MiNK Therapeutics Reports First $200,000 Product Revenue From agenT-797 in Q3 2026

MiNK Therapeutics reported its first pre-commercial product revenue, $200,000, from agenT-797 supplied through named-patient access in the third quarter ended September 30, 2026. The clinical-stage biopharmaceutical company, which develops off-the-shelf allogeneic iNKT cell therapies, disclosed the figure in its quarterly results, Stock Titan reported on November 11, 2026.

MiNK's Named-Patient Access and ARDS Trial

MiNK recognized the $200,000 from agenT-797 supplied on a paid, per-patient basis under its international named-patient access program, in collaboration with Orphan Drug Consulting and BAP. The program is open in multiple countries outside the United States, and each request originates with a treating physician for an individually identified patient and is authorized case by case by the applicable health authority. agenT-797 remains investigational.

"This quarter, physicians outside our trials began requesting agenT-797 for their patients, bringing our first pre-commercial revenue," said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics.

The randomized, placebo-controlled Phase 2 study of agenT-797 plus standard of care in adults with acute lung injury and moderate-to-severe hypoxemic respiratory failure (C-1300-02) continued enrolling in Lviv, Ukraine, during the quarter. MiNK plans an initial randomized stage of 124 patients for an initial readout in the second half of 2027, with the potential to expand, and is seeking FDA feedback on the development plans.

In September, agenT-797 was selected as the therapeutic cell system for the Draper-led Reversible Ambient Biostabilization team under ARPA-H's BioStabilization Systems (BoSS) program, which is supported by up to $87 million in program-wide funding over four years for performers. MiNK participates on a fixed-fee basis.

MiNK's Cash and Quarterly Losses

According to akta.pro company records, MiNK completed a $5.8 million private placement in May 2024, selling 4,640,000 shares at $1.25 each, and held $9.5 million in cash at the end of the first quarter of 2026. The company ended the third quarter of 2026 with $7.5 million in cash and cash equivalents, compared with $8.8 million at June 30, 2026. Net loss was $2.6 million, or $0.50 per share, compared with $2.9 million, or $0.65 per share, in the prior-year quarter.

MiNK's Path to the Randomized ARDS Study

In May 2026, the first patient was dosed in the randomized Phase 2 trial (C-1300-02) at First Lviv Territorial Medical Union in Ukraine under Ministry of Health authorization, with U.S. sites underway under an active IND, according to akta.pro company records. In August 2026, MiNK presented initial Day 28 observations from the first agenT-797-treated patients at the Military Health System Research Symposium, Seeking Alpha reported on August 13, 2026. MiNK reported a quarterly loss of $0.62 per share for the second quarter, missing the consensus estimate of $0.60 by $0.02, Ticker Report reported on August 14, 2026.

MiNK's Next Steps Into 2027

MiNK expects U.S. dosing in C-1300-02 before year-end 2026 and plans to meet with the FDA before year-end on the adaptive Phase 2b/3 design. The University of Wisconsin–Madison has informed MiNK that it expects the first patient in its investigator-sponsored Phase 1 GvHD prevention study to be scheduled by December 2026.